Disposition of 17700 shares by Peterson Katharine of Acrivon Therapeutics at 5.7 subject to Rule 16b-3

ACRV Stock   6.13  0.58  8.64%   
Slightly above 61% of Acrivon Therapeutics,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Acrivon Therapeutics, Common suggests that many traders are alarmed. Acrivon Therapeutics,'s investing sentiment can be driven by a variety of factors including economic data, Acrivon Therapeutics,'s earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Acrivon Therapeutics Common Officer: Chief Accounting Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 17700 stock option (right to buy) at 5.7 of Acrivon Therapeutics by Peterson Katharine on 13th of May 2024. This event was filed by Acrivon Therapeutics Common with SEC on 2024-05-13. Initial filing of beneficial ownership - SEC Form 3

Cash Flow Correlation

Acrivon Therapeutics,'s cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Acrivon Therapeutics,'s relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Acrivon Therapeutics, Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Acrivon Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Acrivon Therapeutics, Fundamental Analysis

We analyze Acrivon Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Acrivon Therapeutics, is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Acrivon Therapeutics, Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acrivon Therapeutics, stock to make a market-neutral strategy. Peer analysis of Acrivon Therapeutics, could also be used in its relative valuation, which is a method of valuing Acrivon Therapeutics, by comparing valuation metrics with similar companies.

Peers

Acrivon Therapeutics, Related Equities

ANEBAnebulo Pharmaceuticals   29.60   
0%
100.0%
MLYSMineralys Therapeutics,   2.43   
0%
8.0%
AVTEAerovate Therapeutics   1.56   
0%
5.0%
OPTOpthea   0.55   
0%
1.0%
RZLTRezolute   0.68   
2.0%
0%
MOLNMolecular Partners   2.39   
8.0%
0%
PMVPPmv Pharmaceuticals   2.65   
8.0%
0%
ANTXAN2 Therapeutics   2.86   
9.0%
0%
ANABAnaptysBio   4.54   
15.0%
0%
ADAGAdagene   5.37   
18.0%
0%

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.